Abivax ADR (NASDAQ:ABVX)’s traded shares stood at 0.34 million during the last session, with the company’s beta value hitting 0.28. At the close of trading, the stock’s price was $7.12, to imply a decrease of -7.05% or -$0.54 in intraday trading. The ABVX share’s 52-week high remains $17.02, putting it -139.04% down since that peak but still an impressive 1.69% since price per share fell to its 52-week low of $7.00. The company has a valuation of $450.98M, with an average of 0.19 million shares in intraday trading volume over the past 10 days and average of 144.60K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Abivax ADR (ABVX), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give ABVX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Abivax ADR (NASDAQ:ABVX) trade information
After registering a -7.05% downside in the last session, Abivax ADR (ABVX) has traded red over the past five days. The 5-day price performance for the stock is -8.25%, and -16.24% over 30 days. With these gigs, the year-to-date price performance is -33.46%. Short interest in Abivax ADR (NASDAQ:ABVX) saw shorts transact 0.48 million shares and set a 5.08 days time to cover.
The extremes give us $42 and $42 for target low and target high price respectively. As such, ABVX has been trading -489.89% off suggested target high and -489.89% from its likely low.
Abivax ADR (ABVX) estimates and forecasts
The rating firms project that company’s revenue will grow 72.36% compared to the previous financial year.
Revenue forecast for the current quarter as set by 1 analysts is 3.41M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 1.7M.
ABVX Dividends
Abivax ADR has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
We also have Franklin Strategic Series-Franklin Biotechnology Discove and abrdn World Healthcare Fund as the top two Mutual Funds with the largest holdings of the Abivax ADR (ABVX) shares. Going by data provided on Jul 31, 2024 , Franklin Strategic Series-Franklin Biotechnology Discove holds roughly 480.3 shares. This is just over 0.76% of the total shares, with a market valuation of $3.42 million. Data from the same date shows that the other fund manager holds a little less at 316.43, or 0.50% of the shares, all valued at about 2.25 million.
